Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.64 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.53 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903928 | 0.95 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1TRAP1HSP90B1WNT1 | |
| SCHEMBL10263316 | 0.92 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1TRAP1HSP90B1ROCK2 | |
| SCHEMBL904241 | 0.90 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1 | |
| SCHEMBL904064 | 0.90 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1 | |
| SCHEMBL902130 | 0.89 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1TRAP1HSP90B1NUDT1 | |
| SCHEMBL15091218 | 0.89 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL904214 | 0.89 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL10255525 | 0.89 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL10254685 | 0.88 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL10253669 | 0.87 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | claimed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | claimed |
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.